Wide Ranks

ARCT

Arcturus Therapeutics Holdings

17.51

Top Statistics
Market Cap 474 M Forward PE -11.81 Revenue Growth -7.70 %
Current Ratio 4.76 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -39.05 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.46 Enterprise / Revenue 1.66 Price To Sales Trailing12 Months 2.96
Profitability
Profit Margins -39.05 % Operating Margins -25.77 %
Balance Sheet
Total Cash 237 M Total Cash Per Share 8.76 Total Debt 29 M
Total Debt To Equity 11.24 Current Ratio 4.76 Book Value Per Share 9.67
All Measures
Short Ratio 1175.00 % Message Board Id finmb_235062181 Shares Short Prior Month 4 M
Return On Equity -0.2312 City San Diego Uuid cb9a2721-c1b9-3b25-9cc5-ea57e34e4857
Previous Close 16.93 First Trade Date Epoch Utc 1 B Book Value 9.67
Beta 2.64 Total Debt 29 M Volume 221467
Price To Book 1.81 Last Split Date 1 B Fifty Two Week Low 14.93
Total Cash Per Share 8.76 Total Revenue 160 M Shares Short Previous Month Date 1 B
Target Median Price 71.00 Audit Risk 10 Max Age 86400
Recommendation Mean 1.30 Sand P52 Week Change 0.3133 Operating Margins -25.77 %
Target Mean Price 79.47 Net Income To Common -62643000 Short Percent Of Float 0.2595
Implied Shares Outstanding 27 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 568870 Average Volume10days 568870 Total Cash 237 M
Next Fiscal Year End 1 B Revenue Per Share 5.96 Held Percent Insiders 0.0846
Ebitda Margins -48.01 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 6 Regular Market Previous Close 16.93
Target Low Price 44.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 20.02
Open 17.13 Free Cashflow -40255376 State CA
Dividend Yield 0.00 % Return On Assets -0.1215 Time Zone Short Name EST
Board Risk 3 Trailing Eps -2.33 Day Low 16.92
Address1 10628 Science Center Drive Shares Outstanding 27 M Compensation Risk 8
Price Hint 2 Target High Price 140.00 Website https://arcturusrx.com
52 Week Change -0.2686 Average Volume 392451 Forward Eps -2.23
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 384.90 %
Last Split Factor 1:7 Regular Market Day High 17.71 Is_sp_500 False
Profit Margins -39.05 % Debt To Equity 11.24 Fifty Two Week High 45.00
Day High 17.71 Shares Short 4 M Regular Market Open 17.13
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 1.66
Revenue Growth -7.70 % Shares Percent Shares Out 0.1656 Operating Cashflow -60092000
Currency USD Time Zone Full Name America/New_York Market Cap 474 M
Is_nasdaq_100 False Zip 92121 Quote Type EQUITY
Industry Biotechnology Long Name Arcturus Therapeutics Holdings Inc. Overall Risk 7
Regular Market Day Low 16.92 Held Percent Institutions 0.9018 Current Price 17.51
Address2 Suite 250 Enterprise To Ebitda -3.46 Financial Currency USD
Current Ratio 4.76 Gross Margins -17.21 % Industry Disp Biotechnology
Number Of Analyst Opinions 9 Country United States Float Shares 24 M
Two Hundred Day Average 26.23 Governance Epoch Date 1 B Enterprise Value 266 M
Price To Sales Trailing12 Months 2.96 Forward PE -11.81 Regular Market Volume 221467
Ebitda -77007000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases.

Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis.

Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial.

Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.